BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol 2022:S0923-7534(22)00110-7. [PMID: 35176457 DOI: 10.1016/j.annonc.2022.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Uson Junior PLS, Bearss J, Babiker HM, Borad MJ. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials. Expert Opin Investig Drugs 2023;:1-7. [PMID: 36714945 DOI: 10.1080/13543784.2023.2173064] [Reference Citation Analysis]
2 Pestana RC, Serrano C. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1079909] [Reference Citation Analysis]
3 Das S, Hayden J, Sullivan T, Rieger-Christ K. The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment. Int J Mol Sci 2023;24. [PMID: 36674480 DOI: 10.3390/ijms24020964] [Reference Citation Analysis]
4 Shang S, Liu J, Hua F. Protein acylation: mechanisms, biological functions and therapeutic targets. Signal Transduct Target Ther 2022;7:396. [PMID: 36577755 DOI: 10.1038/s41392-022-01245-y] [Reference Citation Analysis]
5 Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JM. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers (Basel) 2022;14. [PMID: 36551707 DOI: 10.3390/cancers14246223] [Reference Citation Analysis]
6 Bhamidipati D, Subbiah V. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies. Trends Cancer 2022:S2405-8033(22)00252-7. [PMID: 36494311 DOI: 10.1016/j.trecan.2022.11.003] [Reference Citation Analysis]
7 de Braud F, Valle J, Lamarca A, Malka D, Hollebecque A. Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine. EMJ Oncol 2022. [DOI: 10.33590/emjoncol/10184268] [Reference Citation Analysis]
8 Storandt MH, Jin Z, Mahipal A. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Expert Rev Anticancer Ther 2022;22:1265-74. [PMID: 36408971 DOI: 10.1080/14737140.2022.2150168] [Reference Citation Analysis]
9 Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, López JA, Montesion M, Nimeiri H, Parikh AR, Roychowdhury S, Schwemmers S, Silverman IM, Vogel A. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open 2022;7:100641. [PMID: 36462464 DOI: 10.1016/j.esmoop.2022.100641] [Reference Citation Analysis]
10 Esposito A, Stucchi E, Baronchelli M, Di Mauro P, Ferrari M, Lorini L, Gurizzan C, London NRJ, Hermsen M, Lechner M, Bossi P. Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers. J Clin Med 2022;11. [PMID: 36431263 DOI: 10.3390/jcm11226787] [Reference Citation Analysis]
11 Bilim V, Kuroki H, Shirono Y, Murata M, Hiruma K, Tomita Y. Advanced Bladder Cancer: Changing the Treatment Landscape. JPM 2022;12:1745. [DOI: 10.3390/jpm12101745] [Reference Citation Analysis]
12 Gadaleta-Caldarola G, Rizzo A, Dadduzio V, Lombardi L, Gadaleta-Caldarola A, Infusino S, Cusmai A, Citrigno C, Palmiotti G. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Curr Oncol 2022;29:7925-31. [PMID: 36290903 DOI: 10.3390/curroncol29100626] [Reference Citation Analysis]
13 Ellinghaus P, Neureiter D, Nogai H, Stintzing S, Ocker M. Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End? Cells 2022;11:3180. [PMID: 36231142 DOI: 10.3390/cells11193180] [Reference Citation Analysis]
14 Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, Hudson R, Sridhara R, Ison G, Amiri-Kordestani L, Tang S, Gwise T, Rahman A, Pazdur R, Theoret MR. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. J Clin Oncol 2022;:JCO2200371. [PMID: 36095296 DOI: 10.1200/JCO.22.00371] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rudloff U. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert Opin Emerg Drugs 2022;27:345-68. [PMID: 36250721 DOI: 10.1080/14728214.2022.2134346] [Reference Citation Analysis]
16 Peng J, Sridhar S, Siefker-Radtke AO, Selvarajah S, Jiang DM. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now. Curr Treat Options Oncol 2022. [PMID: 35962938 DOI: 10.1007/s11864-022-01009-4] [Reference Citation Analysis]
17 Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 2022. [PMID: 35948633 DOI: 10.1038/s41586-022-05066-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lim EC, Lim SW, Tan KJ, Sathiya M, Cheng WH, Lai KS, Loh JY, Yap WS. In-Silico Analysis of Deleterious SNPs of FGF4 Gene and Their Impacts on Protein Structure, Function and Bladder Cancer Prognosis. Life (Basel) 2022;12:1018. [PMID: 35888106 DOI: 10.3390/life12071018] [Reference Citation Analysis]
19 Lüdde T, Boulter L. Joining the dots - NEDDylation in cancer cells regulates the tumour environment in cholangiocarcinoma. J Hepatol 2022;77:12-4. [PMID: 35490843 DOI: 10.1016/j.jhep.2022.04.018] [Reference Citation Analysis]
20 Ji T, Chen X, Yeleswaram S. Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling. CPT Pharmacom & Syst Pharma 2022;11:894-905. [DOI: 10.1002/psp4.12805] [Reference Citation Analysis]
21 Shree Harini K, Ezhilarasan D, Lakshmi T. Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment. Oral Oncol 2022;132:105983. [PMID: 35753264 DOI: 10.1016/j.oraloncology.2022.105983] [Reference Citation Analysis]
22 Bayle A, Martin-Romano P, Loriot Y. FIGHT against FGF/FGFR alterations: what are the next steps? Ann Oncol 2022;33:460-2. [PMID: 35450697 DOI: 10.1016/j.annonc.2022.03.014] [Reference Citation Analysis]
23 Wang Z, Anderson KS. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer. Cancer J 2022;28:354-62. [PMID: 36165723 DOI: 10.1097/PPO.0000000000000615] [Reference Citation Analysis]